埃森哲：COVID-19： 领导生命科学领域的诚信与信任 -埃森哲（英文版）.pdf

1、NOWNEXTWhat to do Now, What to do NextCovid-19: Life sciences industry anchor response Leading with Integrity in Response to Covid-19 NOWNEXTWhat to do Now, What to do NextCovid-19: Copyright2020AccentureAllrightsreserved. COVID-19 is a global crisis, evolving at unprecedented speed and scale. The l

2、ife sciences industry is at the epicenter of developing tests and treatments and getting them to the people that need them around the world. At this critical time, life sciences companies are challenged to continue to advance treatments across therapeutic portfolios while ensuring supply, protecting

3、 employees, and adapting for business continuity and innovation. Copyright2020AccentureAllrightsreserved. As the life sciences industry works, invests and collaborates tirelessly to fast-track testing and treatment for COVID-19, they must also continue to advance their pipelines and rethink ways of

4、bringing treatments to patients- people depend on it. As a result of social distancing, an unprecedented separation between patients and healthcare providers (HCPs) is necessary to mitigate the spread of COVID-19. As a result, life sciences companies must virtualize their reach and engagement to the

5、m relationships with healthcare providers and caring for people depends on it. The supply chain is impacted as life sciences companies manage challenges supplying clinical trials and overcoming logistical hurdles while ensuring quality and safety in manufacturing. Life sciences companies must adapt

6、their supply chains to address these issues peoples health depends on it. People working in life sciences are adapting to new ways of connecting. People are less able to convene in person to advance scientific progress, educate healthcare providers and provide patient care and support. The industry